In vitro cytotoxicity and in vivo efficacy, pharmacokinetics, and metabolism of 10074-G5, a novel small-molecule inhibitor of c-Myc/Max dimerization.
The c-Myc oncoprotein is overexpressed in many tumors and is essential for maintaining the proliferation of transformed cells. To function as a transcription factor, c-Myc must dimerize with Max via the basic helix-loop-helix leucine zipper protein (bHLH-ZIP) domains in each protein. The small molecule 7-nitro-N-(2-phenylphenyl)-2,1,3-benzoxadiazol-4-amine (10074-G5) binds to and distorts the bHLH-ZIP domain of c-Myc, thereby inhibiting c-Myc/Max heterodimer formation and inhibiting its transcriptional activity. We report in vitro cytotoxicity and in vivo efficacy, pharmacodynamics, pharmacokinetics, and metabolism of 10074-G5 in human xenograft-bearing mice. In vitro, 10074-G5 inhibited the growth of Daudi Burkitt's lymphoma cells and disrupted c-Myc/Max dimerization. 10074-G5 had no effect on the growth of Daudi xenografts in C.B-17 SCID mice that were treated with 20 mg/kg 10074-G5 intravenously for 5 consecutive days. Inhibition of c-Myc/Max dimerization in Daudi xenografts was not seen 2 or 24 h after treatment. Concentrations of 10074-G5 in various matrices were determined by high-performance liquid chromatography-UV, and metabolites of 10074-G5 were identified by liquid chromatography/tandem mass spectrometry. The plasma half-life of 10074-G5 in mice treated with 20 mg/kg i.v. was 37 min, and peak plasma concentration was 58 μM, which was 10-fold higher than peak tumor concentration. The lack of antitumor activity probably was caused by the rapid metabolism of 10074-G5 to inactive metabolites, resulting in tumor concentrations of 10074-G5 insufficient to inhibit c-Myc/Max dimerization. Our identification of 10074-G5 metabolites in mice will help design new, more metabolically stable small-molecule inhibitors of c-Myc.
Clausen
Dana M
DM
Molecular Therapeutics/Drug Discovery Program, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania 15213, USA.
Guo
Jianxia
J
Parise
Robert A
RA
Beumer
Jan H
JH
Egorin
Merrill J
MJ
Lazo
John S
JS
Prochownik
Edward V
EV
Eiseman
Julie L
JL
D000825:Animal Structures / Q000378:metabolism; D000818:Animals; D051778:Basic Helix-Loop-Helix Leucine Zipper Transcription Factors / Q000037:antagonists & inhibitors / Q000378:metabolism*; D001798:Blood Proteins / Q000378:metabolism; D045744:Cell Line, Tumor; D002470:Cell Survival / Q000187:drug effects; D004317:Doxorubicin / Q000627:therapeutic use; D005243:Feces / Q000737:chemistry; D005260:Female; D005965:Glucuronates / Q000378:metabolism; D005966:Glucuronidase / Q000378:metabolism; D018922:HL-60 Cells; D006801:Humans; D020128:Inhibitory Concentration 50; D008099:Liver / Q000378:metabolism; D051379:Mice; D016513:Mice, SCID; D009369:Neoplasms / Q000378:metabolism / Q000473:pathology; D010069:Oxadiazoles / Q000378:metabolism / Q000493:pharmacokinetics* / Q000494:pharmacology* / Q000627:therapeutic use / Q000633:toxicity; D010949:Plasma / Q000378:metabolism; D011485:Protein Binding / Q000187:drug effects; D055503:Protein Multimerization / Q000187:drug effects*; D016271:Proto-Oncogene Proteins c-myc / Q000037:antagonists & inhibitors / Q000378:metabolism*; D053719:Tandem Mass Spectrometry; D013844:Thiazoles / Q000494:pharmacology; D016896:Treatment Outcome; D014556:Urine / Q000737:chemistry; D023041:Xenograft Model Antitumor Assays
C534883:10074-G5; C524814:5-(4-ethylbenzylidene)-2-thioxothiazolidin-4-one; D051778:Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; D001798:Blood Proteins; D005965:Glucuronates; C499330:MAX protein, human; C489427:MYC protein, human; D010069:Oxadiazoles; D016271:Proto-Oncogene Proteins c-myc; D013844:Thiazoles; D004317:Doxorubicin; D005966:Glucuronidase
Exp Hematol. 2006 Nov;34(11):1480-9
17046567
Oncogene. 1999 May 13;18(19):3004-16
10378696
Science. 2002 Jul 5;297(5578):102-4
12098700
Oncogene. 2001 Sep 10;20(40):5595-610
11607812
Nucleic Acids Res. 1997 Apr 15;25(8):1493-501
9162900
Cancer Res. 1986 Mar;46(3):1535-8
2417706
Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8164-9
12808131
Oncogene. 2003 Sep 18;22(40):6151-9
13679853
Cancer Chemother Pharmacol. 2009 Mar;63(4):615-25
18509642
Comput Programs Biomed. 1983 Jun;16(3):203-16
6688572
Am J Hematol. 2001 Jun;67(2):84-92
11343379
Mol Cell Biol. 2000 Apr;20(7):2423-35
10713166
Proc Natl Acad Sci U S A. 2006 Apr 18;103(16):6344-9
16606833
Anticancer Drugs. 2007 Feb;18(2):161-70
17159602
Oncogene. 2008 Mar 20;27(13):1905-15
17906696
Curr Opin Chem Biol. 2008 Aug;12(4):464-71
18706517
Chem Biol. 2006 Jul;13(7):745-51
16873022
J Steroid Biochem Mol Biol. 2006 Dec;102(1-5):147-55
17052904
J Am Chem Soc. 2009 Jun 3;131(21):7390-401
19432426
Nature. 2008 Oct 2;455(7213):679-83
18716624
Chem Biol. 2008 Nov 24;15(11):1149-55
19022175
Proc Natl Acad Sci U S A. 1982 Dec;79(24):7824-7
6961453
J Pharmacol Exp Ther. 2003 Jan;304(1):37-47
12490573
J Med Chem. 2009 Mar 12;52(5):1247-50
19215087
Cell. 2002 May 3;109(3):321-34
12015982
Bioorg Med Chem. 2006 Apr 15;14(8):2660-73
16384710
Bioorg Med Chem Lett. 2009 Nov 1;19(21):6038-41
19800226
J Pediatr Surg. 2006 Jan;41(1):207-11; discussion 207-11
16410134
Bioorg Med Chem Lett. 2009 Feb 1;19(3):807-10
19114306
Cancer Res. 2007 Oct 15;67(20):9762-70
17942906
Mol Cell Biol. 1999 Jan;19(1):1-11
9858526
Proc Natl Acad Sci U S A. 2002 Mar 19;99(6):3830-5
11891322
Mol Cell Biol. 2001 Feb;21(3):691-702
11154257
J Pharmacokinet Biopharm. 1978 Feb;6(1):79-98
650423
Mol Cancer Ther. 2007 Sep;6(9):2399-408
17876039
Toxicol Ind Health. 1997 Jul-Aug;13(4):407-84
9249929
Mol Cell. 1999 Aug;4(2):199-207
10488335